The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2026 | Early genomic profiling in pancreatic cancer: matching biomarkers to neoadjuvant therapy
Jeremy Kratz, MD, University of Wisconsin Carbone Cancer Center, Madison, WI, discusses early genomic profiling in pancreatic cancer. Clinical trials increasingly use biomarkers for upfront/neoadjuvant therapies. Early comprehensive genomic profiling is critical to match variants (KRAS mutations, rare variants, molecular subtypes) to treatment strategies. This interview took place at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
